Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Seven Corners Capital Management, LLC. This analysis is provided for institutional research purposes only and is not investment advice.
"Seven Corners Capital's equity portfolio gained approximately 17% in 2023, bringing its cumulative performance since 2020 to roughly 102%. The fund maintains a concentrated allocation across major deep-value and sum-of-the-parts positions including Pershing Square Holdings, Genworth Financial, Merrimack Pharmaceuticals, and Sandridge Energy, each benefiting from clear upcoming catalysts, asset discount narrowing, or capital return programs."
Seven Corners Capital reported a 17% gain for its equity portfolio in 2023, outperforming its four-year stacked benchmark baseline since 2020 with a cumulative 102% appreciation versus 56% for the S&P 500. Guided by a long-term, patient investing approach, the fund concentrates its capital in deep-value, sum-of-the-parts, and special-situation investments with asymmetric risk-reward profiles. The portfolio's top position, Pershing Square Holdings (30% allocation), trades at a significant NAV discount while preparing for potential corporate restructuring and a U.S. operating company listing. Genworth Financial (13% position) offers sum-of-the-parts value driven by its majority stake in Enact Holdings and prospective organizational de-stacking. Merrimack Pharmaceuticals (11% position) represents a debt-free, market-uncorrelated play anticipating a major FDA decision and associated $225 million CVR payout for Onivyde. Sandridge Energy (9% position) leverages strong free cash flow conversion, low decline rates, and energy price tailwinds while returning excess capital through special and regular dividends. Overall, Seven Corners Capital remains positioned to capitalize on structural discount narrowing and specific corporate catalysts across its core holdings.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Assigned 0.85 given high portfolio concentration across four specific top positions (30% PSHZF, 13% GNW, 11% MACK, 9% SD) with explicit cost bases and defined corporate catalysts.
Growth Outlook
Assigned 0.55 as the manager expresses mild optimism regarding specific deep-value positions and commodity tailwinds while remaining focused on idiosyncratic company catalysts.
Risk Appetite
Assigned 0.75 reflecting concentrated allocation to high-conviction equity positions, with 63% of assets allocated across four core holdings.
Capital Deployment
Assigned 0.50 as the fund is maintaining existing positions with minimal portfolio turnover, adhering to its stated low-turnover, patient strategy.
Forward Guidance
Assigned 0.50 indicating a hold-and-monitor posture as portfolio companies execute capital returns, corporate restructurings, and regulatory submissions.
Language Signal
Assigned 0.75 due to predominantly bullish language focusing on asset undervaluation, free cash flow conversion, sum-of-the-parts discounts, and open-market insider buying.
Perceived Risk
Assigned 0.35 because general macro risk discussion is minimal and framed largely around how inflation dynamics benefit energy holdings.
Opportunity Density
Assigned 0.65 as the manager identifies high-margin, mispriced opportunities in corporate restructurings and CVR plays, maintaining focus on its existing holdings.
Time Horizon
Assigned 0.85 reflecting a multi-year investment horizon, explicit quotes endorsing patient sloth-like holding, and focus on long-term structural value realization.
